<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01590303</url>
  </required_header>
  <id_info>
    <org_study_id>UWO HSREB #18803</org_study_id>
    <nct_id>NCT01590303</nct_id>
  </id_info>
  <brief_title>Outcome Following Vitamin C Administration in Sepsis</brief_title>
  <official_title>A Pilot Study Examining the Efficacy of Vitamin C Administration in Septic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine if Vitamin C administration to septic patients will
      result in an improvement in organ dysfunction which occurs during a septic illness.

      Hypothesis: 1. Vitamin C in sepsis will reduce the injury to organs 2. Vitamin C will reduce
      the length of time on a ventilator, length of stay in the intensive care unit and in
      hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will measure biomarkers of inflammation, coagulation and oxidative stress. These
      biomarkers have been shown to be increased during periods of oxidative stress eg
      post-operative, trauma, sepsis. The investigators will determine if Vitamin C administration
      decreases oxidative stress and as a result, a decrease in the markers of organ dysfunction eg
      SOFA Scores. Ultimately, if the investigators show a decrease in injury to organs, will this
      result in a better outcome for patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequential organ function assessment score (SOFA)</measure>
    <time_frame>28 days or discharge from intensive care unit</time_frame>
    <description>Scoring system to determine the extent of a patient's organ function or rate of failure. The score based on 6 different scores; one each for respiratory, hepatic, cardiovascular, renal, coagulation, neurologic.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers as a measure of coagulation, inflammation and oxidative stress.</measure>
    <time_frame>28 days or discharge from intensive care unit</time_frame>
    <description>Vitamin C Assays - Plasma/WBC Cytokines (8- plex) Adhesion Molecules Procalcitonin C-Reactive Protein,H igh Sensitivity High Density Lipoprotein Cholesterol Tbars F2 isoprostane Neutrophil elastase Thrombomodulin Free DNA HIF-1Î±</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Sepsis</condition>
  <arm_group>
    <arm_group_label>Vitamin C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous Vitamin C will be administered (1 gram) every 8 hours for 28 days or discharge from intensive care unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo vehicle administered in same fashion as active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit</description>
    <arm_group_label>Vitamin C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of severe sepsis

          -  admitted to the intensive care unit

        Exclusion Criteria:

          -  allergy to Vitamin C

          -  history of kidney stones

          -  glucose-6-phosphate dehydrogenase deficiency

          -  history of iron overload/hemochromatosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael D Sharpe, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tracey Bentall, RN</last_name>
    <phone>5196858500</phone>
    <phone_ext>32546</phone_ext>
    <email>tracey.bentall@lhsc.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael D Sharpe, MD FRCPC</last_name>
    <phone>5196633030</phone>
    <email>michael.sharpe@lhsc.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Sharpe, MD FRCPC</last_name>
      <email>michael.sharpe@lhsc.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Tracey Bentall, RN</last_name>
      <phone>5196858500</phone>
      <email>tracey.bentall@lhsc.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Norman Smith, MSc, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claudio Martin, MD FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tina Mele, MD FRCPC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2012</study_first_posted>
  <last_update_submitted>May 1, 2012</last_update_submitted>
  <last_update_submitted_qc>May 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Michael Sharpe</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>severe sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

